Factors Associated with Utilization of Dipeptidyl-4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Retrospective Study

International Journal of Endocrinology

Volumn 2014, Issue , 2014, Pages

  Zaman Huri, Hasniza ^a,b   Selamat, Norfarahen ^a   Vethakkan, Shireene Ratna ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; METFORMIN PLUS SITAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN;

ADULT; AGED; ARTICLE; BODY MASS; CROSS-SECTIONAL STUDY; DRUG UTILIZATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VERY ELDERLY;

EID: 84934911609     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2014/367564     Document Type: Article

References (29)

1. International Diabetes Federation, IDF Diabetes Atlas Update 2012, 2012, http://www.idf.org/sites/default/files/EN 6E Atlas Full 0.pdf.
2. International Diabetes Federation, 2012, http://www.idf.org/types-diabetes.
3. Ministry of Health Malaysia, The Future of Diabetes in Malaysia, Malaysian Diabetes Educators Society Seminar, 2012.
4. Pharmaceutical Services Division and the Clinical Research Centre, "Malaysian Statistics on Medicine", 2007, http://www.pharmacy.gov. my/v2/sites/default/files/document-upload/msom2007.pdf.
5. American Diabetes Association, "Standard of medical care in diabetes", Diabetes Care, vol. 36, no. 1, pp. S11-S66, 2013.
6. H. Duez, B. Cariou, and B. Staels, "DPP-4 inhibitors in the treatment of type 2 diabetes", Biochemical Pharmacology, vol. 83, no. 7, pp. 823-832, 2012.
7. R. Pathak and M. B. Bridgeman, "Dipeptidyl peptidase-4 (DPP-4) inhibitors in the management of diabetes", Pharmacy and Therapeutics, vol. 35, no. 9, pp. 509-513, 2010.
8. Malaysian Dia betes Association, "A New Approach to Type 2 Diabetes Drug Treatment is Now Available in Malaysia", 2007, http://www.diabetes.org.my/article.php?aid=202.
9. Ministry of Health Malaysia, Drug Formulary, Ministry of Health Malaysia, 2013.
10. A. J. Bergman, J. Cote, B. Yi et al., "Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor", Diabetes Care, vol. 30, no. 7, pp. 1862-1864, 2007.
11. M. Mafauzy, "Diabetes control and complications in public hospitals in Malaysia", Medical Journal of Malaysia, vol. 61, no. 4, pp. 477-483, 2006.
12. M. Eid, M. Mafauzy, and A. R. Faridah, "Glycaemic control of type 2 diabetic patients on follow up at Hospital Universiti Sains Malaysia", The Malaysian Journal of Medical Sciences, vol. 10, no. 2, pp. 40-49, 2003.
13. M. Mafauzy, Z. Hussein, and S. P. Chan, "The status of diabetes control in Malaysia: results of Diab Care 2008", Medical Journal of Malaysia, vol. 66, no. 3, pp. 175-181, 2011.
14. B. H. Chew, I. Mastura, P. Y. Lee et al., "Ethnic differences in glycaemic control and complications: the adult diabetes control and management (ADCM), Malaysia", Medical Journal of Malaysia, vol. 66, no. 3, p. 245, 2011.
15. J. E. Shaw, R. A. Sicree, and P. Z. Zimmet, "Global estimates of the prevalence of diabetes for 2010 and 2030", Diabetes Research and Clinical Practice, vol. 87, no. 1, pp. 4-14, 2010.
16. M. Mafauzy, "Diabetes control and complications in private primary healthcare in Malaysia", Medical Journal of Malaysia, vol. 60, no. 2, pp. 212-217, 2005.
17. Malaysian Ministry of Healt, "National Health Morbidity Survey IV Kuala Lumpur", Institute of Public Health Malaysia, 2012.
18. Ministry of Health Malaysia, Malaysian Society of Hypertension, and Academy of Medicine, Clinical Practice Guideline. "Management of Hypertension", Ministry of Health Malaysia, Kuala Lumpur, Malaysia, 3rd edition, 2008.
19. I. Truter, "An investigation into antidiabetic medication prescribing in South Africa", Journal of Clinical Pharmacy and Therapeutics, vol. 23, no. 6, pp. 417-422, 1998.
20. C. H. Po and A. Todd, "Drug utilization review of dipeptidyl peptidase-4 (DPP-4) inhibitors in Alice Ho Miu Ling Nethersole Hospital (AHNH)", in Proceedings of the Hong Kong Pharmacy Conference, 2012.
21. B. Ahrén, "Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin-diabetes control and potential adverse events", Best Practice & Research: Clinical Endocrinology & Metabolism, vol. 23, no. 4, pp. 487-498, 2009.
22. Ministry of Health Malaysia/Malaysian Endocrine & Metabolic Society/Academy of Medicine & Malaysian Diabetes Association: Clinical Practice Guideline, Management of Type 2 Diabetes Mellitus, Ministry of Health Malaysia, Kuala Lumpur, Malaysia, 4th edition, 2009.
23. A. Khalam, C. Dilip, and C. Shinu, "Drug use evaluation of diabetes mellitus in hospitalized patients of a tertiary care referral hospital", Journal of Basic and Clinical Physiology and Pharmacology, vol. 23, no. 4, pp. 173-177, 2012.
24. National Institute for Health and Clinical Excellence (NICE), Type 2 Diabetes: The Management of Type 2 Diabetes, 2009, http://www.nice.org.uk/nicemedia/pdf/CG66NICEGuideline.pdf.
25. S. L. Schwartz, "Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors", The American Journal Geriatric Pharmacotherapy, vol. 8, no. 5, pp. 405-418, 2010.
26. B. Wai, L. G. Kearney, D. L. Hare, M. Ord, L. M. Burrell, and P. M. Srivastava, "Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control", Cardiovascular Diabetology, vol. 11, no. 1, pp. 1-5, 2012.
27. Ministry of Health Malaysia, Malaysian Society for The Study of Obesity Clinical Practice Guideline, Management of Obesity Ministry of Health Malaysia, Kuala Lumpur, Malaysia, 2004.
28. Ministry of Health Malaysia, and National Heart Association of Malaysia & Academy of Medicine, Clinical Practice Guideline: Management of Dyslipidemia (4th Ed), Ministry of Health Malaysia, Kuala Lumpur, Malaysia, 2011.
29. World Health Organization & International Diabetes Association, Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus, WHO, Geneva, Switzerland, 2011.